She found a four-leaf
clover in the meadow, which is considered lucky.
她在草地上找到了一个四叶幸运草，这被认为是带来好运的。
The sheep grazed peacefully on the
clover-filled field.
羊群平静地在长满三叶草的田野上吃草。
Clover is often used as a cover crop to enrich the soil with nitrogen.
三叶草常被用作覆盖作物，以向土壤中添加氮元素来丰富土壤。
He wore a shamrock, the national symbol of Ireland, on his lapel.
他在翻领上戴着一个象征爱尔兰国家标志的三叶草。
The
clover sprouted quickly after the spring rain.
春雨过后，三叶草迅速发芽了。
The farmer rotated his crops, alternating corn and
clover to improve soil fertility.
农民轮作作物，交替种植玉米和三叶草以提高土壤肥力。
Clover honey has a mild flavor that many people enjoy.
三叶草蜂蜜味道温和，很多人都喜欢。
The bees were busy collecting nectar from the
clover blossoms.
蜜蜂正忙着从三叶草花中采集花蜜。
A patch of red
clover brightened up the otherwise dull landscape.
一片红三叶草为原本单调的风景增添了色彩。
In some cultures, finding a four-leaf
clover is thought to bring good luck.
在某些文化中，找到四叶草被认为能带来好运。
The program called Project Clover will cover the cost of building three data centers, the implementation of privacy enhancing technologies and employment of an independent third-party security company — NCC Group — to audit and verify data controls and protections, as well as monitor data flows, TikTok said in a statement on its official website.
TikTok在其官方网站上的一份声明中表示，名为“三叶草项目”的项目将支付建造三个数据中心、实施隐私增强技术以及聘请独立的第三方安全公司NCC集团审计和验证数据控制和保护以及监控数据流的费用。
This project, called "Project Clover", will cover the cost of building three data centers, implementation of privacy enhancing technologies and the employment of an independent third-party security company NCC Group to audit and verify data controls and protections, TikTok said in a statement on its official website.
TikTok在其官方网站上的一份声明中表示，这个名为“三叶草项目”的项目将包括建造三个数据中心、实施隐私增强技术以及聘请独立的第三方安全公司NCC Group来审计和验证数据控制和保护的费用。
The Chinese-owned short video platform TikTok has announced a series of data security measures named "Project Clover" amid the tightened regulations on data security in Europe.
随着欧洲数据安全法规的收紧，中国拥有的短视频平台TikTok宣布了一系列名为“三叶草计划”的数据安全措施。
Clover Biopharmaceuticals Ltd, a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutic candidates, announced on Wednesday the construction of a new research and development center in Zhangjiang Biotech and Pharmaceutical Industrial Base in Shanghai.
三叶草生物制药有限公司，一家开发新型疫苗和候选生物治疗药物的全球临床生物技术公司，周三宣布在上海张江生物技术和制药工业基地建设一个新的研发中心。
Clover intends to recruit hundreds of new hires from the area's deep talent pool to supplement its existing R&D capabilities and accelerate the development of multiple new product candidates.
三叶草计划从该地区的深层人才库中招聘数百名新员工，以补充其现有的研发能力，并加快开发多种新产品。
Joshua Liang, chief executive officer of Clover Biopharmaceuticals, said: "Establishing a new R&D center in Shanghai will allow us to expand our R&D capabilities and accelerate our innovative pipeline.
三叶草生物制药首席执行官Joshua Liang表示：“在上海建立一个新的研发中心将使我们能够扩大研发能力，加快我们的创新渠道。
Clover Biopharmaceuticals, a Chinese clinical-stage biopharma company developing vaccines and oncology drugs, announced on Wednesday that its protein-based COVID-19 vaccine candidate was found to be 67 percent effective against COVID-19 of any degree of severity and 79 percent against the highly infectious Delta variant in a large late-stage trial.
中国临床阶段生物制药公司——三叶草生物制药有限公司周三宣布，其基于蛋白质的新冠疫苗在一项大型后期试验中被发现对任何严重程度的新冠肺炎的有效率为67%，对高传染性的德尔塔变异毒株的有效率为79%。
"SPECTRA (the name of the project for the trial) enrolled participants during a time when the world encountered the rapid spread of increasingly transmissible SARS-CoV-2 variants and a takeover by Delta," said Joshua Liang, chief executive officer of Clover Biopharmaceuticals.
SPECTRA（试验项目的名称）在世界面临传播速度越来越快的SARS-CoV-2变异毒株，以及Delta变异毒株逐渐占据主导地位的时候招募了参与者，"Clover Biopharmaceuticals的首席执行官Joshua Liang表示。
Clover plans to submit conditional market approval applications to China's National Medical Products Administration, the European Medicines Agency, and World Health Organization in the fourth quarter of the year.
Clover计划在今年第四季度向中国国家药品监督管理局(NMPA)、欧洲药品管理局(EMA)和世界卫生组织(WHO)提交有条件市场批准申请。
Clover Biopharmaceuticals, a global clinical-stage biotechnology company, announced on Tuesday the completion of targeted enrollment of adult and elderly participants in the Spectra project, or the Study Evaluating Protective-Efficacy and Safety of Clover's Trimeric Recombinant Protein-based and Adjuvanted COVID-19 Vaccine.
全球临床阶段生物技术公司Clover Biopharmaceuticals周二宣布，已完成Spectra项目的目标成人和老年人参与者招募，该项目即评估Clover基于三聚体重组蛋白和佐剂的COVID-19疫苗保护效力和安全性的研究。
The study is a global pivotal Phase 2/3 clinical trial evaluating the efficacy, safety and immunogenicity of SCB-2019 (CpG 1018/Alum), Clover's COVID-19 vaccine candidate.
这项研究是一项全球性的关键性2/3期临床试验，旨在评估SCB-2019（CpG 1018/Alum），即Clover公司COVID-19疫苗候选产品的有效性、安全性和免疫原性。
Given the geographic diversity of Spectra, Clover expects to announce a robust dataset in the third quarter of 2021, including an analysis of efficacy across the major currently circulating strains of SARS-CoV-2, including variants of concern and variants of interest.
考虑到Spectra的地理多样性，Clover预计将在2021年第三季度发布一个全面的数据集，其中包括对目前主要流通的SARS-CoV-2各毒株（包括关注变种和兴趣变种）疫苗有效性的分析。
Pending positive data from Spectra, Clover plans to submit conditional regulatory approval applications to China's National Medical Products Administration, the European Medicines Agency and World Health Organization.
在收到Spectra的积极数据后，Clover计划向中国的国家药品监督管理局、欧洲药品管理局及世界卫生组织提交有条件监管批准申请。
Clover continues to plan to commence product launch of SCB-2019 (CpG 1018/Alum) by the end of 2021 and recently signed an advance purchase agreement with the Global Alliance for Vaccines and Immunization, committing up to 414 million doses to the COVAX facility.
康希诺生物计划在2021年底之前启动SCB-2019 (CpG 1018/Alum)产品的上市，并最近与全球疫苗和免疫联盟(GAVI)签署了预购协议，承诺向COVAX机制提供多达4.14亿剂疫苗。
Clover also expects to supply doses to countries directly via government procurement and/or bilateral supply agreements.
Clover还预计通过政府采购和/或双边供应协议直接向各国提供疫苗剂量。
Chinese clinical-stage biotech Clover Biopharmaceuticals and Nasdaq-listed Dynavax Technologies Corp, a biopharmaceutical company focused on developing and commercializing novel vaccines, announced on Wednesday a commercial supply agreement of Dynavax's CpG 1018TM advanced adjuvant for use in Clover's protein-based COVID-19 vaccine candidate, SCB-2019 (CpG 1018/Alum).
周三，中国临床阶段生物技术公司Clover Biopharmaceuticals和纳斯达克上市生物制药公司Dynavax Technologies Corp宣布了一项商业供应协议，Dynavax将为其先进的CpG 1018TM佐剂提供给Clover，用于其基于蛋白质的COVID-19疫苗候选产品SCB-2019 (CpG 1018/Alum)。
Clover separately announced on Wednesday an advanced purchase agreement with Gavi, the Vaccine Alliance, for supplying up to 414 million doses of SCB-2019 (CpG 1018/Alum) through 2022 for the COVAX facility.
Clover还在周三单独宣布与全球疫苗联盟(Gavi, the Vaccine Alliance)达成预购协议，将在2022年底前通过“新冠肺炎疫苗实施计划”(COVAX)为后者供应至多4.14亿剂SCB-2019（CpG 1018/Alum）疫苗。
Pending conditional regulatory approvals, Clover expects to commence product launch of SCB-2019 (CpG 1018/Alum) by the end of 2021, supplying the COVAX facility and countries directly via government procurement and/or bilateral supply agreements.
在等待条件性的监管批准，Clover预计将在2021年底开始推出SCB-2019 (CpG 1018/Alum)疫苗产品，通过COVAX机制向各国供应，并直接通过政府采购和/或双边供应协议进行。
Clover is currently advancing SPECTRA, a global pivotal Phase 2/3 clinical trial evaluating the efficacy, safety, and immunogenicity of SCB-2019 (CpG 1018/Alum), and expects interim data for vaccine efficacy around the middle of 2021.
Clover正在积极推进SPECTRA，这是一项全球性的关键性2/3期临床试验，旨在评估SCB-2019（CpG 1018/Alum）疫苗的有效性、安全性和免疫原性。公司预计在2021年中左右获得中期的疫苗效力数据。
Pending positive interim data, Clover plans to submit conditional regulatory approval applications to the European Medicines Agency, China's National Medical Products Administration and the World Health Organization in the second half of 2021.
在获得积极的中期数据后，Clover计划在2021年下半年向欧洲药品管理局、中国国家药品监督管理局和世界卫生组织提交有条件监管批准申请。
Clover Biopharmaceuticals, a clinical-stage Chinese biotech developing novel vaccines and biologic therapeutic candidates to address the world's most life-threatening diseases and public health threats, announced on Wednesday an advance purchase agreement with Gavi, or the Vaccine Alliance.
中国临床阶段生物技术公司Clover Biopharmaceuticals周三宣布与全球疫苗免疫联盟(Gavi, 简称：疫苗联盟)达成预购协议。Clover Biopharmaceuticals是一家致力于开发创新疫苗和生物治疗候选药物、旨在应对世界上最致命疾病和公共卫生威胁的中国临床阶段生物技术公司。
Pending an Emergency Use Listing from the World Health Organization for Clover's COVID-19 vaccine candidate, Clover will make an initial 64 million doses available for procurement through the COVAX facility in 2021.
在等待世界卫生组织对Clover的COVID-19疫苗候选产品的紧急使用清单的同时，Clover将在2021年通过COVAX机制初步提供6400万剂疫苗供采购。
The agreement also contains the opportunity to access Clover variant-adapted COVID-19 vaccine candidates.
该协议还包含了获取针对变异株优化的 Clover COVID-19 疫苗候选产品的途径。
In exchange for these commitments, Clover will receive a significant upfront payment, a payment upon positive Phase-2/3 data, and additional advance payments upon Gavi's exercise of options for doses to be delivered in 2022.
作为对这些承诺的回报，Clover将获得一大笔预付款，当取得积极的2/3期数据时将获得另一笔款项，如果Gavi行使在2022年交付疫苗剂量的期权，Clover还将获得额外的预付款。
Gavi will allocate Clover's COVID-19 vaccine doses to the AMC (Advanced Market Commitment)-eligible and self-financing participants under a tiered pricing plan.
Gavi将根据分层定价计划，将Clover的COVID-19疫苗剂量分配给先进市场承诺（AMC）符合条件的参与者以及自筹资金的参与者。
Clover will further receive additional payments upon the delivery of the doses of its COVID-19 vaccine at all pricing tiers, including doses being delivered to the AMC-eligible participants.
Clover将进一步获得额外付款，这些付款将在所有价格层级的COVID-19疫苗剂量交付时支付，包括向AMC合格参与者交付的剂量。
Joshua Liang, CEO of Clover Biopharmaceuticals, said the company is grateful for the support from Gavi, the Coalition for Epidemic Preparedness Innovations, and other COVAX partners in the joint pursuit of supporting global equitable access of COVID-19 vaccines and helping protect at-risk groups in participating countries.
Clover Biopharmaceuticals的首席执行官梁朋表示，公司对于Gavi、流行病预防创新联盟以及其它COVAX合作伙伴在共同追求支持全球公平获取COVID-19疫苗及帮助保护参与国家中的高风险群体所给予的支持表示感激。
Chinese clinical-stage biotech Clover Biopharmaceuticals and Nasdaq-listed biopharmaceutical company Dynavax Technologies Corporation announced on Wednesday the first participants have been dosed in Clover's global Phase 2/3 clinical trial evaluating the efficacy, safety and immunogenicity of its protein-based S-Trimer COVID-19 vaccine candidate adjuvanted with Dynavax's CpG 1018 plus alum.
中国临床阶段生物技术公司三叶草生物制药和纳斯达克上市生物制药公司Dynavax Technologies Corporation周三宣布，三叶草全球II/III期临床试验已开始给药，该试验旨在评估其基于蛋白质的S-Trimer新冠疫苗候选产品与Dynavax的CpG 1018加佐剂联合使用在疗效、安全性和免疫原性方面的表现。
Joshua Liang, CEO of Clover Biopharmaceuticals, said there is still a significant need in many global communities for COVID-19 vaccines and should the Phase 2/3 interim analysis be favorable, the company will work closely with regulatory authorities worldwide to make the S-Trimer COVID-19 vaccine candidate available as soon as possible.
Clover Biopharmaceuticals的首席执行官Joshua Liang表示，全球许多社区对COVID-19疫苗的需求仍然很大。如果2/3期临床试验的中期分析结果积极，公司将与世界各地的监管机构紧密合作，尽快使S-Trimer COVID-19疫苗候选产品投入使用。
Ryan Spencer, CEO of Dynavax, said Clover's adjuvanted vaccine candidate has the potential to be an important additional solution to address worldwide demand, since it can be manufactured at large scale and stored at standard refrigeration temperature.
Dynavax的首席执行官Ryan Spencer表示，Clover的佐剂疫苗候选产品有可能成为解决全球需求的重要额外方案，因为它可以大规模生产，并且可以在标准冷藏温度下储存。
In December 2020, Clover reported positive clinical data from its Phase 1 trial, demonstrating its protein-based COVID-19 S-Trimer vaccine candidate in combination with Dynavax's CpG 1018 induces strong immune response, including neutralizing antibodies and cell-mediated immunity, as well as favorable safety and tolerability profiles in the adult and elderly participants.
在2020年12月，Clover报告了其Phase 1试验的积极临床数据，显示其基于蛋白质的COVID-19 S-Trimer疫苗候选产品与Dynavax的CpG 1018结合，能够诱导强烈的免疫反应，包括中和抗体和细胞介导的免疫反应，以及在成人和老年参与者中具有良好的安全性和耐受性特征。
Clover Biopharmaceuticals, a Chinese clinical-stage biotechnology company developing transformative biologics for the world's most debilitating diseases, announced the completion of an oversubscribed $230 million round of Series C financing on Tuesday.
中国临床阶段的生物技术公司—— Clover Biopharmaceuticals 宣布完成了一轮超额认购的2.3亿美元C系列融资。该公司致力于为世界上最令人衰弱的疾病开发变革性的生物药物。
This financing brings Clover's total capital raised in the last 12 months to over $400 million.
这笔融资使Clover在过去12个月中筹集的总资本超过4亿美元。
The proceeds will support the continued development and expansion of Clover's pipeline of protein-based vaccines and biologic cancer therapies utilizing its innovative and proprietary Trimer-Tag technology platform.
这些资金将用于支持Clover持续开发和扩展其利用创新且专有的Trimer-Tag技术平台开发的蛋白质基疫苗和生物癌症疗法管线。
Clover expects to initiate a global Phase 2/3 efficacy trial for SCB-2019 (S-Trimer), its COVID-19 vaccine candidate, in the first half of 2021 and has initiated production planning for potentially hundreds of millions of vaccine doses in 2021.
Clover计划在2021年上半年开始在全球范围内进行SCB-2019（S-Trimer）的2/3期疗效试验，这是其COVID-19疫苗候选产品。该公司已开始规划2021年可能生产数亿剂疫苗的生产计划。
Clover has also initiated development of additional vaccine programs including multivalent SARS-CoV-2 (covering multiple variants), rabies and influenza.
Clover也已开始开发其他疫苗项目，包括多价SARS-CoV-2（覆盖多种变体）、狂犬病和流感疫苗。
Clover also expects to advance multiple new pipeline products to the clinic in 2021 and further expand its in-house R&D and cGMP commercial biomanufacturing capabilities.
此外，Clover预计将在2021年将多个新管线产品推进到临床阶段，并进一步扩展其内部的R&D和cGMP商业化生物制造能力。
Michael Yi, co-CIO and partner of Hillhouse Capital, said Clover has had a tremendous year of growth with the rapid advancement of the COVID-19 S-Trimer vaccine candidate through clinical development, and its robust and differentiated pipeline of vaccines and biologic therapeutics hold great promise to make a difference in other areas.
高瓴资本的联席首席投资官及合伙人Michael Yi表示，Clover在COVID-19 S-Trimer疫苗候选产品快速推进临床开发的推动下，度过了一个增长迅猛的年份。该公司丰富且具有差异化的疫苗和生物治疗药物管线显示出巨大的潜力，有望在其他领域产生影响。
In China's most high-profile import-themed fair, Cytiva signed a string of deals with Wego, Zhifei, Clover and Jinbo, pledging to invest in the fields of manufacturing, bioprocess development and research to accelerate the development and manufacture of therapeutics and benefit patients in the country and beyond.
在备受瞩目的中国进口博览会上，Cytiva与Wego、Zhifei、Clover和Jinbo等公司签署了一系列协议，承诺投资于制造、生物工艺开发和研究领域，以加快治疗药物的开发和生产，造福中国乃至全球的患者。
Another highlight was Cytiva's support of Clover Biopharmaceuticals to scale up the output of its vaccine candidate, paving the way for the production of COVID-19 vaccines in the future.
另一个亮点是Cytiva支持 Clover Biopharmaceuticals 扩大其疫苗候选产品的产量，为未来生产COVID-19疫苗铺平了道路。
The Coalition for Epidemic Preparedness Innovations, an innovative partnership launched at Davos in 2017 between public, private, philanthropic and civil organizations to develop vaccines to stop future epidemics, announced Tuesday that it will fund the development of the protein-based S-Trimer COVID-19 vaccine candidate by China's Sichuan Clover Biopharmaceuticals Inc through to licensure, including a global pivotal Phase 2/3 efficacy clinical study beginning before the end of 2020, if the vaccine is proven to be safe and effective.
2017年在达沃斯成立的创新公私合作联盟“流行病防范创新联盟”(Coalition for Epidemic Preparedness Innovations, CEPI)周二宣布，如果这种疫苗被证明是安全有效的，它将资助中国四川 Clover 生物制药公司(Sichuan Clover Biopharmaceuticals)研发的基于蛋白质的 S-Trimer 新冠疫苗候选产品，直至获得许可。这包括在2020年底之前启动一项全球关键性的二期/三期临床试验。
The coalition's total investment in Clover's S-Trimer vaccine candidate will be up to $328 million, including previously announced commitments of $69.5 million, which have funded preclinical studies and Phase 1 clinical trials, preparations for the global pivotal Phase 2/3 efficacy study and initial manufacturing scale-up activities.
该联盟对Clover的S-Trimer疫苗候选产品的总投资将达到3.28亿美元，包括先前宣布的6950万美元承诺资金，这些资金已经用于资助临床前研究和第1期临床试验，以及全球关键性的第2/3期疗效研究的准备工作和初期制造规模扩张活动。
Clover said it is exploring development pathways for the S-Trimer vaccine to be made accessible to populations in China and globally, if it is proven to be safe and effective.
Clover公司表示，如果S-三聚体疫苗被证明是安全有效的，该公司正在探索将其开发路径用于中国乃至全球人群的途径。
The expanded partnership is a result of Clover's successful early stage clinical development of the S-Trimer vaccine candidate.
这一扩大合作是由于Clover在S-Trimer疫苗候选药物的早期临床开发阶段取得了成功。
Promising preclinical and preliminary Phase 1 data – which will be published in a peer-reviewed publication in the near future - indicate that S-Trimer is well-tolerated and produces strong neutralizing antibody and Th1-biased cell-mediated immune responses, which merit ongoing evaluation of the vaccine candidate, Clover said in a press release.
Clover公司在一个新闻发布会上表示，即将在一份同行评审的出版物上发表的有希望的临床前和初步1期数据显示，S-Trimer耐受性良好，并能产生强效的中和抗体和Th1偏向的细胞介导免疫反应，这使得该疫苗候选物值得继续评估。
The jet is decorated with elements of the China International Import Expo and features the mascot holding a four-leaf clover.
In the past financial year, in China, the Singapore company invested in Black Lake Technologies, a provider of manufacturing operation management software solutions; Genki Forest, an innovative healthy beverage company; and Clover Biopharmaceuticals, a biopharma company developing vaccines and oncology drugs.
Joshua Liang, CEO of Clover Pharmaceuticals, said Chinese local pharmaceutical and biotech companies are attracting not only China-born talent, but also more foreign expertise and returning Chinese.
Clover Pharmaceuticals首席执行官Joshua Liang表示，中国本土制药和生物科技公司正吸引着的不仅有在华出生的人才，还有越来越多的外籍专家及回流的中国人才。
Clover has been able to attract top talent from around the world to join its COVID-19 vaccine development program, and currently has employees in the United States, Europe, Southeast Asia and Latin America.
Clover 已成功吸引全球各地的顶尖人才加入其 COVID-19 疫苗研发项目，目前其员工分布在美国、欧洲、东南亚以及拉丁美洲。
In 2016, Clover had no more than 15 people, who were all lab-based scientists.
2016年时，Clover的员工数量不超过15人，且全部为实验室科研人员。
Pending an emergency use listing from the World Health Organization for its COVID-19 vaccine candidate, Clover is to provide up to 414 million doses of its protein-based COVID-19 vaccine candidate for procurement through COVAX, including 64 million doses available in 2021.
在等待世界卫生组织对其新冠疫苗候选产品的紧急使用清单审批期间，Clover 将通过 COVAX 机制提供最多 4.14 亿剂其基于蛋白质技术的新冠疫苗候选产品，其中 2021 年可供应 6400 万剂。
While Sinopharm is a State-owned giant, both Sinovac and Clover are not State-owned enterprises, and represent a growing group of private pharmaceutical and biotech companies in China rising to significance with impressive innovation capabilities, cutting-edge technologies and robust R&D pipelines.
虽然中国生物是国有企业巨头，但科兴和三叶草均不属于国有企业，它们代表了中国一批正在崛起的私营制药和生物科技企业。这些企业凭借令人瞩目的创新实力、尖端技术和强大的研发管线日益彰显其重要性。
Joshua Liang, CEO of Clover, said many Chinese biotech companies－mostly non-State-owned firms－have been able to quickly become large and fully integrated biotech companies, which is quite rare in Western countries.
Clover公司首席执行官Joshua Liang表示，许多中国生物科技公司——大部分为非国有企业——已迅速成长为规模庞大且全面整合的生物科技企业，这在西方国家颇为罕见。
未经许可，严禁转发。QQ交流群：688169419